Sandy Nassif1, Jorn Wichmann2, Dominic Strube3, Stratos Vassis2, Hans Christiansen2, Diana Steinmann2. 1. Clinic for Radiotherapy and Special Oncology of the Hannover Medical School, Hannover, Germany; nassif.sandy@mh-hannover.de. 2. Clinic for Radiotherapy and Special Oncology of the Hannover Medical School, Hannover, Germany. 3. University of Applied Sciences, Technology, Business and Design Wismar, Wismar, Germany.
Abstract
BACKGROUND/AIM: The implementation of a platinum-containing regimen is recommended for definitive and adjuvant therapy of patients with locally advanced head and neck tumour. We compared the conditions for the use of cisplatin or carboplatin/paclitaxel or for changing between these two regimens on a clinic-specific basis. PATIENTS AND METHODS: We evaluated 150 patients with advanced head and neck squamous cell carcinoma who received simultaneous radiochemotherapy at our institution between 2012 and 2017. Chemotherapy with weekly doses of cisplatin (40 mg/m2, group 1) or, in cases of impaired renal and/or cardiac function, with weekly doses of carboplatin AUC2 and paclitaxel (45 mg/m2, group 2), was performed as a first-choice therapy. If toxicities occurred in group 1, treatment was switched to the carboplatin/paclitaxel regimen (group 3). Patient- and therapy-related parameters, toxicity and survival data were compared across groups. RESULTS: We examined 99, 30, and 21 patients in each group who received at least 1 course of chemotherapy. Group 3 patients switched from cisplatin to carboplatin/paclitaxel after a median of 3 courses due to nephrotoxicity (95.2%). The target of at least 5 chemotherapy courses was most frequently achieved by patients in group 1 (69.7%), followed by group 3 (61.9%) and then group 2 (40.0%). Multivariate analysis revealed that patients who switched groups were more likely to be over 60 years old (p=0.021), undergo definitive radiochemotherapy (p=0.049) and develop higher nephrotoxicity (p=0.036) than group 1 patients. Outcomes did not differ between groups. CONCLUSION: When cisplatin application is contraindicated due to renal- or cardiotoxicity, carboplatin/paclitaxel is an appropriate option. Copyright
BACKGROUND/AIM: The implementation of a platinum-containing regimen is recommended for definitive and adjuvant therapy of patients with locally advanced head and neck tumour. We compared the conditions for the use of cisplatin or carboplatin/paclitaxel or for changing between these two regimens on a clinic-specific basis. PATIENTS AND METHODS: We evaluated 150 patients with advanced head and neck squamous cell carcinoma who received simultaneous radiochemotherapy at our institution between 2012 and 2017. Chemotherapy with weekly doses of cisplatin (40 mg/m2, group 1) or, in cases of impaired renal and/or cardiac function, with weekly doses of carboplatin AUC2 and paclitaxel (45 mg/m2, group 2), was performed as a first-choice therapy. If toxicities occurred in group 1, treatment was switched to the carboplatin/paclitaxel regimen (group 3). Patient- and therapy-related parameters, toxicity and survival data were compared across groups. RESULTS: We examined 99, 30, and 21 patients in each group who received at least 1 course of chemotherapy. Group 3 patients switched from cisplatin to carboplatin/paclitaxel after a median of 3 courses due to nephrotoxicity (95.2%). The target of at least 5 chemotherapy courses was most frequently achieved by patients in group 1 (69.7%), followed by group 3 (61.9%) and then group 2 (40.0%). Multivariate analysis revealed that patients who switched groups were more likely to be over 60 years old (p=0.021), undergo definitive radiochemotherapy (p=0.049) and develop higher nephrotoxicity (p=0.036) than group 1 patients. Outcomes did not differ between groups. CONCLUSION: When cisplatin application is contraindicated due to renal- or cardiotoxicity, carboplatin/paclitaxel is an appropriate option. Copyright
Authors: S S Agarwala; E Cano; D E Heron; J Johnson; E Myers; V Sandulache; S Bahri; R Ferris; Y Wang; A Argiris Journal: Ann Oncol Date: 2007-07 Impact factor: 32.976
Authors: David E Dawe; David Christiansen; Anand Swaminath; Peter M Ellis; Janet Rothney; Rasheda Rabbani; Ahmed M Abou-Setta; Ryan Zarychanski; Salaheddin M Mahmud Journal: Lung Cancer Date: 2016-07-18 Impact factor: 5.705
Authors: Stephan Maring; Khaled Elsayad; Markus Stenner; Claudia Rudack; Uwe Haverkamp; Jan Rehkämper; Eva Wardelmann; Hans T Eich Journal: Oncol Res Treat Date: 2018-11-13 Impact factor: 2.825
Authors: M Suntharalingam; M L Haas; B A Conley; M J Egorin; S Levy; S Sivasailam; J M Herman; M C Jacobs; W C Gray; R A Ord; J A Aisner; D A Van Echo Journal: Int J Radiat Oncol Biol Phys Date: 2000-04-01 Impact factor: 7.038
Authors: B Singh; M Bhaya; J Stern; J T Roland; M Zimbler; R M Rosenfeld; G Har-El; F E Lucente Journal: Laryngoscope Date: 1997-11 Impact factor: 3.325
Authors: Dirk Rades; Daniel Seidl; Stefan Janssen; Amira Bajrovic; Katarina Karner; Primoz Strojan; Steven E Schild Journal: BMC Cancer Date: 2016-07-08 Impact factor: 4.430
Authors: Erik Haehl; Alexander Rühle; Hélène David; Tobias Kalckreuth; Tanja Sprave; Raluca Stoian; Christoph Becker; Andreas Knopf; Anca-Ligia Grosu; Nils H Nicolay Journal: Radiat Oncol Date: 2020-02-04 Impact factor: 3.481